IRONWOOD PHARMACEUTICALS INC
Close on Oct 19, 2026
- Market cap
- $595.16M
- P/E (TTM)
- 4.6
- Dividend yield
- –
About Ironwood Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Ironwood Pharmaceuticals, Inc. is a biotechnology company that researches, develops, and commercializes therapies for individuals affected by gastrointestinal and rare diseases. Its primary commercial medicine is linaclotide, branded as LINZESS and CONSTELLA, which is a guanylate cyclase type C agonist. The business also advances clinical-stage drug candidates, notably apraglutide for short bowel syndrome. Its treatments serve adult and pediatric patients with conditions such as irritable bowel syndrome with constipation, chronic idiopathic constipation, and functional constipation.
The company was incorporated in Delaware and operates globally through strategic collaborations with pharmaceutical partners across North America, Europe, and Asia. Its commercialized product is distributed in multiple international markets, including the United States, Canada, Mexico, China, and Japan, alongside various European nations such as the United Kingdom, Italy, and Spain. Manufacturing and distribution activities rely on networks of third-party contract suppliers and regional pharmaceutical partners.
Summary of the business section of Ironwood Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- IRONWOOD PHARMACEUTICALS INC
- Founded
- 1998
- Headquarters
- Boston, MA
- Address
- 100 Summer Street, Suite 2300 02110
- Phone
- (617) 621-7722
- Website
- www.ironwoodpharma.com
- Employees
- 100, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- IRWD
- Exchange
- Nasdaq
- IPO date
- Feb 4, 2010
- Shares outstanding
- 165M, Jul 31, 2026
- Public float
- $102.69M, Jun 30, 2025
- Filer category
- Accelerated filer<br>Smaller reporting company
- SEC CIK
- 1446847
- CUSIP
- 46333X108
- ISIN
- US46333X1081
- LEI
- 549300PC8MR6QHH6P296
- EIN
- 04-3404176
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Thomas A. MCCOURT | Chief Executive Officer, Director | 1,898,838 |
| Jeffrey Silber | SVP, CMO, Head-Res&Drug | 137,036 |
| Ronald Silver | PFO & PAO | 755,250 |
| Tammi L. Gaskins | Chief Commercial Officer | 350,350 |
| Michael Shetzline | SVP, CMO, Head-Res&Drug | 1,179,462 |
| Minardo John | Chief Legal Officer | 500,498 |
| Gregory S. Martini | Chief Financial Officer | 297,213 |
| Sravan Kumar Emany | SVP, COO and CFO | 309,572 |
| Andrew Davis | SVP, Chief Business Officer | 284,685 |
| Alexander J. Denner | Director | 18,710,619 |
| Jay Shepard | Director | 235,036 |
| Jon R. Duane | Director | 253,820 |
| Julie McHugh | Director | 410,693 |
| Mark G. Currie | Director | 676,900 |
| Catherine Moukheibir | Director | 181,425 |
| Marla L. Kessler | Director | 229,364 |
| Andrew Dreyfus | Director | 228,313 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr.McCourt | $1.95M | $1.29M | $1.21M | $27 | – |
| FY2024 Mr.McCourt | $6.08M | -$4.49M | $2.82M | $36 | – |
| FY2024 Thomas Mc Court | $6.08M | -$4.49M | $2.82M | $36 | – |
| FY2023 Mr.McCourt | $7.58M | $4.63M | $2.62M | $92 | – |
| FY2023 Thomas Mc Court | $7.58M | $4.63M | $2.62M | $92 | – |
| FY2022 Thomas Mc Court | $7.89M | $10.16M | $2.30M | $93 | $111 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 100 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 10, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Jun 3, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 27, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 3, 2025 | Late filing | Notification of late filing |
| Jun 30, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 31, 2023 | Tender offer | Third-party tender offer for the company's shares |
| Apr 4, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 9, 2017 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 3, 2016 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 4, 2010 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 1, 2010 | Listing | Registration of securities on an exchange (Form 8-A) |